Recent News
November 1, 2023
Nectero Medical Granted Breakthrough Therapy Designation for the Nectero EAST® System to Treat Infrarenal AAA
Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today…
August 24, 2023
Nectero Medical Receives FDA Fast Track Designation for Nectero EAST® System
Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced…
July 24, 2023
Nectero Medical Announces Clearance of IND Application to Initate Phase II/III Clinical Trial of Nectero East® System
Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease and improve…
September 10, 2021
Nectero Medical Completes $19.5 Million Series C Financing
Nectero Medical Inc. today announced the closing of its $19.5 million Series C financing round, led by…
April 30, 2020
Nectero Medical Completes Initial Closing of Series B Financing
Nectero Medical Inc. today announced the closing of its $19.5 million Series C financing round, led by…
-
April 11, 2024
Nectero Medical Announces Completion of $96M Series D Financing
-
January 18, 2024
Nectero Medical Announces Initiation of Phase II/III Clinical Trial of the Nectero EAST® System for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms
-
November 1, 2023
Nectero Medical Granted Breakthrough Therapy Designation for the Nectero EAST® System to Treat Infrarenal AAA
-
August 24, 2023
Nectero Medical Receives FDA Fast Track Designation for Nectero EAST® System
-
July 24, 2023
Nectero Medical Receives FDA Clearance of IND Application to Initiate Phase II/III Clinical Trial of Nectero EAST® System for Treatment of Small- to Mid-Sized Abdominal Aortic Aneurysms
-
September 10, 2021
Nectero Medical Completes $19.5 Million Series C Financing